A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Ritonavir (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 23 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 22 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.